Can tranexamic acid (TXA) stop a gastrointestinal bleed?

Can TXA Stop a GI Bleed?

Tranexamic acid (TXA) should NOT be routinely used to stop gastrointestinal bleeding, as current high-quality evidence shows no mortality benefit and potential harm, particularly increased thromboembolic events and seizures. 1

Guideline Recommendations

Lower GI Bleeding

• The British Society of Gastroenterology (2019) explicitly recommends that TXA use in acute lower GI bleeding be confined to clinical trials only. 1
• While older pooled analyses of upper GI bleeding trials showed a 40% mortality reduction, this benefit disappeared when limited to trials at low risk of bias. 1
• The studies supporting TXA were conducted before modern endoscopic therapy and high-dose acid suppression became standard, making their applicability to current practice uncertain. 1

Variceal Bleeding

• The EASL (2022) strongly recommends AGAINST using TXA in patients with cirrhosis and active variceal bleeding. 1
• The HALT-IT trial (n=12,009 patients, ~50% suspected variceal bleeding) showed no benefit in reducing death from bleeding within 5 days. 1
• TXA showed an almost 2-fold increase in venous thromboembolic events, with risk concentrated in patients with liver disease/suspected variceal bleeding. 1
• The hypofibrinolytic state frequently present in critically ill cirrhotic patients may explain why antifibrinolytics are ineffective. 1

Non-Variceal Upper GI Bleeding

• Older guidelines (2002) noted that while TXA reduced need for surgical intervention, it did not reduce ulcer rebleeding, and further studies were needed before routine use could be recommended. 1
• The 2019 International Consensus Group guidelines do not recommend TXA for non-variceal upper GI bleeding. 1

Evidence from Recent Meta-Analyses

Harm Profile

The most concerning findings come from high-quality recent studies:

• Increased seizure risk: RR 1.73 (95% CI 1.03-2.93) 1, 2
• Increased thromboembolic events: Fixed-effect analysis showed OR 1.28 (95% CI 1.07-1.55) 3
• No mortality benefit: Multiple meta-analyses confirm no significant reduction in death 4, 3, 2

Potential Benefits (Context-Dependent)

Some meta-analyses suggest limited benefits in specific scenarios:

• Reduced rebleeding rates: Particularly in upper GI bleeding when low-dose/enteral TXA used (RR 0.64,95% CI 0.45-0.91) 5, 4, 3
• Reduced need for surgery: Low-dose IV/enteral TXA showed RR 0.58 (95% CI 0.38-0.88) 4
• No effect on lower GI bleeding: A prospective RCT showed no difference in transfusion requirements for lower GI bleeding 6

Dosing Considerations (If Used Off-Label)

The FDA-approved indication for TXA is for hemophilia patients undergoing tooth extraction, NOT gastrointestinal bleeding. 7

High-dose extended regimen (used in HALT-IT, associated with harm):

• Loading dose: 1g IV over 10 minutes
• Maintenance: 3g IV over 24 hours 4

Low-dose regimen (some evidence of benefit in upper GI bleeding):

• Various protocols used in older trials
• Generally lower total doses than trauma protocols 4

Critical Distinctions

Upper vs. Lower GI Bleeding

• Upper GI bleeding: Some older evidence suggests potential benefit, but modern guidelines do not recommend routine use 1, 5, 8
• Lower GI bleeding: No benefit demonstrated; guideline explicitly recommends against use outside trials 1, 6

Variceal vs. Non-Variceal

• Variceal bleeding: Strong recommendation AGAINST use due to lack of benefit and increased thrombotic risk 1
• Non-variceal bleeding: Insufficient evidence to support routine use 1

Common Pitfalls to Avoid

1. Do not extrapolate from trauma data: TXA's proven benefit in trauma (CRASH-2 trial) does not translate to GI bleeding 1

2. Timing matters in trauma, not GI bleeding: While TXA must be given within 3 hours in trauma for benefit, this principle has not been validated for GI bleeding 1

3. Avoid in patients with cirrhosis: Increased thrombotic risk and no demonstrated benefit 1

4. Route of administration: FDA labeling emphasizes FOR INTRAVENOUS USE ONLY to avoid inadvertent neuraxial injection causing seizures 7

5. Contraindications per FDA: Active intravascular clotting, subarachnoid hemorrhage, severe hypersensitivity 7

Current Standard of Care

For acute GI bleeding, focus on:

• Hemodynamic resuscitation 1
• Early endoscopy with therapeutic intervention 1
• High-dose proton pump inhibitors for non-variceal upper GI bleeding 1
• Vasoactive therapy for variceal bleeding 1
• Reversal of anticoagulation when appropriate 1
• Restrictive transfusion strategy 1

TXA has no established role in routine clinical practice for GI bleeding and should only be considered in the context of clinical trials. 1